Schulz Solveig, Helmholz Thekla, Schmitt Johannes, Franke Kornelia, Otto Hans-Jürgen, Weise Wolfgang
Department of Obstetrics and Gynecology, Otto-von-Guericke-University, Magdeburg, Germany.
Breast Cancer Res Treat. 2002 Apr;72(3):221-6. doi: 10.1023/a:1014972520302.
[111In-DTPA-D-Phe1]-octreotide scintigraphy has been shown to reveal somatostatin receptor-positive lesions in the majority of primary breast cancers. We have recently developed a panel of somatostatin receptor subtype-specific antibodies that effectively stain formalin-fixed, paraffin-embedded breast cancer tissue. However, it is uncertain to what extend somatostatin receptors detected during immunohistochemical staining represent functional binding sites responsible for high tracer uptake during somatostatin receptor scintigraphy.
We, therefore, conducted a prospective study in which 23 patients with suspected breast tumors were included. All patients received [111In]-pentetreotide scintigraphy. After surgical removal of the tumor, the somatostatin receptor status was determined by immunohistochemistry.
Among 20 pathologically proven malignant tumors (14 ductal and six lobular carcinomas), 13 (approximately 65%) were scintigraphically visible. Of the 20 primary breast cancer specimens analyzed, three tumors (approximately 15%) were positive for sst1, nine (approximately 45%) revealed immunoreactive sst2A receptors, eight (approximately 40%) showed sst3-like immunoreactivity, and 14 (approximately 70%) were positive for sst5. There was an excellent correlation between the outcome of somatostatin receptor scintigraphy and expression of sst2A (P = 0.025) as well as sst5 (P < 0.001) but not expression of either sst1 (P = 0.343) or sst3 (P = 0.400).
Both sst2A and sst5 can be responsible for high tracer uptake during [111In]-pentetreotide scintigraphy in primary breast cancer. Thus, somatostatin receptor scintigraphy may possibly be of value in the detection of proven somatostatin receptor sst2A- and/or sst5-positive lesions in metastatic breast cancer.
[111铟 - DTPA - D - 苯丙氨酸1] - 奥曲肽闪烁扫描已显示在大多数原发性乳腺癌中可揭示生长抑素受体阳性病变。我们最近开发了一组生长抑素受体亚型特异性抗体，可有效对福尔马林固定、石蜡包埋的乳腺癌组织进行染色。然而，免疫组织化学染色检测到的生长抑素受体在多大程度上代表了生长抑素受体闪烁扫描期间高示踪剂摄取所涉及的功能性结合位点尚不确定。
因此，我们进行了一项前瞻性研究，纳入了23例疑似乳腺肿瘤患者。所有患者均接受了[111铟] - 喷替肽闪烁扫描。手术切除肿瘤后，通过免疫组织化学确定生长抑素受体状态。
在20例经病理证实的恶性肿瘤（14例导管癌和6例小叶癌）中，13例（约65%）在闪烁扫描中可见。在分析的20例原发性乳腺癌标本中，3例肿瘤（约15%）sst1呈阳性，9例（约45%）显示sst2A受体免疫反应阳性，8例（约40%）表现出sst3样免疫反应性，14例（约70%）sst5呈阳性。生长抑素受体闪烁扫描结果与sst2A（P = 0.025）以及sst5（P < 0.001）的表达之间存在极好的相关性，但与sst1（P = 0.343）或sst3（P = 0.400）的表达均无相关性。
sst2A和sst5均可导致原发性乳腺癌在[111铟] - 喷替肽闪烁扫描期间出现高示踪剂摄取。因此，生长抑素受体闪烁扫描在检测转移性乳腺癌中已证实的生长抑素受体sst2A和/或sst5阳性病变方面可能具有价值。
